ATS 2020 Advance Program

BASIC • BEHAVIORAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM A90 EMERGING DANGERS FROM E-CIGARETTES: LET’S HAVE A VAPE DEBATE Assemblies on Environmental, Occupational and Population Health; Clinical Problems; Pediatrics; Respiratory Cell and Molecular Biology; Tobacco Action Committee; Drug/Device Discovery and Development Committee; Environmental Health Policy Committee 2:15 p.m. - 4:15 p.m. Target Audience Health care providers and trainees, public policy advocates and decision makers, tobacco and e-cigarette researchers, critical care physicians Objectives At the conclusion of this session, the participant will be able to: • learn new findings about how nicotine and flavoring chemicals contained in e-cigarette cause adverse health effects in the lung and modify nicotine addiction • improve the ability to effectively advocate for evidence-based public policy initiatives that regulated flavored e-cigarettes to protect young people from nicotine addiction • counsel patients, parents, and teenager, as well as educate the general public about the substantial harms of inhaled flavoring chemicals The use of e-cigarettes is reaching epidemic proportions, especially among teenagers and young adults. An increasing number of vaping-associated acute lung injury cases and other pathologies raise concerns that unique health effects are caused by e-cigarettes. The many different flavors available for these products can by themselves or as reaction products exert toxicities. In addition, high nicotine concentrations delivered as salts likely have distinct health effects. This session will discuss vaping-related clinical manifestations, summarize evidence on how flavoring chemicals and nicotine may cause respiratory toxicity/addiction, and include a patient perspective to provide a real-life story and how this epidemic is affecting people’s lives. Evidence based public policy recommendations will be discussed. Chairing: I. Jaspers, PhD, Chapel Hill, NC S.E. Jordt, PhD, Durham, NC S.A. McGrath-Morrow, MD, Baltimore, MD 2:15 Overview: How Did We Get Here? I. Jaspers, PhD, Chapel Hill, NC 2:30 Patient Perspective: Real Life Implications of E-Cig Addiction G. Sullivan, BS, Philadelphia, PA 2:40 Nicotine and Flavor-Containing E-Liquid Vapors Cause Mucociliary Dysfunction M.A. Salathe, MD, ATSF, Kansas City, KS 2:59 Electronic Cigarette Nicotine-Mediated Lung Damage: Is it Nicotine or DAMPs or Both? S. Ahmad, PhD, Birmingham, AL 3:18 Health Effects of Flavors and Flavor-Solvent Reaction Products in Electronic Cigarette Liquids S.E. Jordt, PhD, Durham, NC 3:37 How Did This Happen? The Strategies Utilized by Electronic Cigarette Device Makers to Reach the Market A.H. Cohen, MD, Menlo Park, CA 3:56 Emerging Data on the Link Between E-Cigarette Use and Acute Lung Injury S.A. McGrath-Morrow, MD, Baltimore, MD BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM A91 ATS CLINICAL PRACTICE GUIDELINES: CLINICAL PRACTICE ON THE CUTTING EDGE Assemblies on Behavioral and Health Services Research; Clinical Problem s ; Critical Care; Pulmonary Infections and Tuberculosis; Sleep and Respiratory Neurobiology; Quality Improvement and Implementation Committee; Documents Development and Implementation Committee ATS 2020 • Philadelphia, PA SUNDAY • MAY 17 61